Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: A possible link between chronic inflammation and uraemic symptoms

Nephrology Dialysis Transplantation

Volumn 24, Issue 6, 2009, Pages 1901-1908

  Schefold, Jörg C ^a   Zeden, Jan Philip ^b   Fotopoulou, Christina ^a   Von Haehling, Stephan ^a   Pschowski, Rene ^a   Hasper, Dietrich ^a   Volk, Hans Dieter ^a   Schuett, Christine ^b   Reinke, Petra ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

IDO; Immune system; Infection; Kynurenine; Renal failure

Indexed keywords

5 HYDROXYTRYPTOPHAN; C REACTIVE PROTEIN; CREATININE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENIC ACID; KYNURENINE; QUINOLINIC ACID; SEROTONIN; TRYPTOPHAN; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; AGE; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BODY WEIGHT; CATABOLISM; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROTONIN BLOOD LEVEL; TANDEM MASS SPECTROMETRY; THERAPY EFFECT; UREMIA;

5-HYDROXYTRYPTOPHAN; ADULT; AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CREATININE; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; KYNURENIC ACID; KYNURENINE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; QUINOLINIC ACID; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SEROTONIN; TRYPTOPHAN; UREMIA;

EID: 67651123081     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn739     Document Type: Article

References (42)

1. Stone TW, Darlington LG. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 2002; 1: 609-620
2. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol 2003; 81: 247-265
3. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993; 45: 309
4. Moronil F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharm 1999; 375: 887
5. Widner B, Leblhuber F, Walli J et al. Degradation of tryptophan in neurodegenerative disorders. Adv Exp Med Biol 1999; 467: 133
6. Rudzite V, Jurika E. Kynurenine and lipid metabolism. Adv Exp Med Biol 1991; 294: 463-466
7. Bertazzo A, Punzi L, Bertazzolo N et al. Tryptophan catabolism in synovial fluid of various arthropathies and its relationship with inflammatory cytokines. Adv Exp Med Biol 1999; 467: 565
8. Sakai N, Saito K, Kaufman S et al. Induction of neopterin synthesis is not required for cytokine-stimulated tryptophan metabolism. Biochem J 1993; 295: 543
9. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-1193
10. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 2007; 7: 817-823
11. Grohmann U, Volpi C, Fallarino F et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 2007; 13: 579-586
12. Sharma MD, Baban B, Chandler P et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117: 2570-2582
13. Penberthy WT. Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease. Curr Drug Metab 2007; 8: 245-266
14. Platten M, Ho P, Youssef S et al. Treatment of autoimmune neuroin-flammation with a synthetic tryptophan metabolite. Science 2005; 310: 850-855
15. Mohib K, Wang S, Guan Q et al. Indoleamine 2,3-dioxygenase expression promotes renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2008; 295: F226-F234
16. Holmes-EW, Russel-PM, Kinzler-GJ et al. Inflammation-associated changes in the cellular availability of tryptophan and kynurenine in renal transplant recipients. Clin Chim Acta 1994; 227: 1-15
17. Suliman ME, Qureshi AR, Stenvinkel P et al. Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. Am J Clin Nutr 2005; 82: 342-349
18. Yoshida R, Hayaishi O. Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. Proc Natl Acad Sci USA 1978; 75: 3998-4000
19. Heikenwalder M, Polymenidou M, Junt T et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynu-cleotide administration. Nat Med 2004; 10: 187-192
20. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005; 106: 2375-2381
21. Grant R, Kapoor V. Inhibition of indoleamine 2,3-dioxygenase activity in IFN-gamma stimulated astroglioma cells decreases intracellular NAD levels. Biochem Pharmacol 2003; 66: 1033-1036
22. Fuchs D, Forsman A, Hagberg L et al. Immune activation and decreased tryptophan in patients with HIV-1 infection. J Interferon Res 1990; 10: 599-603
23. Huang A, Fuchs D, Widner B et al. Tryptophan decrease in advanced colorectal cancer correlates with immune activation and impaired quality of life. Br J Cancer 2002; 86: 1691-1696
24. Topczewska-Bruns J, Pawlak D, Tankiewicz A et al. Kynurenine metabolism in central nervous system in experimental chronic renal failure. Adv Exp Med Biol 2003; 527: 177-182
25. Widner B, Leblhuber F, Walli J et al. Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm 2000; 107: 343-353
26. Saito K, Fujigaki S, Heyes M et al. Mechanism of increases in L-kynurenine and quinolinic acid in renal insufficency. Am J Physiol Renal Physiol 2000; 279: F565
27. Lesaffer G, De Smet R, Lameire N et al. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000; 15: 50-57
28. Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology 2006; 11: 36-41
29. Ridker PM. High-sensitivity C-reactive protein as a predictor of all-cause mortality: implications for research and patient care. Clin Chem 2008; 54: 234-237
30. Oparil S, Oberman A. Nontraditional cardiovascular risk factors. Am JMedSci 1999; 317: 193-207
31. Rao M, Guo D, Perianayagam MC et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. AmJKidneyDis 2005; 45: 324-333
32. Zimmermann J, Herrlinger S, Pruy A et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658
33. Zoccali C, Tripepi G, Mallamaci F. Predictors of cardiovascular death in ESRD. Semin Nephrol 2005; 25: 358-362
34. Stenvinkel P. Inflammation in end-stage renal disease - a fire that burns within. Contrib Nephrol 2005; 149: 185-199
35. Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. NEnglJMed 2002; 347: 1557-1565
36. Whicher J, Biasucci L, Rifai N. Inflammation, the acute phase response and atherosclerosis. Clin Chem Lab Med 1999; 37: 495-503
37. Bolton CH, Downs LG, Victory JG et al. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 2001; 16: 1189-1197
38. Pereira BJ, Shapiro L, King AJ et al. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45: 890-896
39. Knight EL, Rimm EB, Pai JK et al. Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol 2004; 15: 1897-1903
40. Tonelli M, Sacks F, Pfeffer M et al. Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68: 237-245
41. Martinsons A, Rudzite V, Cernevskis H et al. The influence of L-tryptophan peroral load on glomerular filtration rate in chronic glomerulonephritis and chronic renal failure. Adv Exp Med Biol 2003; 527: 37-45
42. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005; 106: 2375-2381